Business Context and Reporting Period
This Form 8-K Current Report was filed by Farmland Partners Inc. on February 25, 2015. The filing addresses corporate governance changes, specifically the resignation of a director and the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Robert S. Solomon resigned as a member of the Board effective immediately on February 25, 2015. His resignation was due to a desire to devote more time to other business interests and was not the result of any disagreement with the Company. He previously served as chairman of the Compensation Committee and a member of the Nominating and Corporate Governance Committee.
- Appointment: Joseph W. Glauber was appointed as a member of the Board on February 25, 2015, to fill the vacancy created by Mr. Solomon's resignation. Dr. Glauber will serve on the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Compensation
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. Regarding compensation for the new appointment:
- Dr. Glauber will receive an annual retainer of $30,000, meeting fees, and expense reimbursements consistent with other independent directors.
- He received a grant of 3,214 restricted shares of common stock under the 2014 Equity Incentive Plan, vesting ratably over three years.
- An indemnification agreement was entered into with Dr. Glauber.
Investor Verification Checklist
- Verify the qualifications and potential conflicts of interest of the new director, Joseph W. Glauber, given his extensive background with the USDA and agricultural policy.
- Confirm the impact of the resignation of Robert S. Solomon on the composition and function of the Compensation Committee.
- Review the Company's 2014 Equity Incentive Plan details regarding the vesting schedule of the 3,214 restricted shares granted to Dr. Glauber.